EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote

Jairo Vinícius Pinto iD, José Alexandre S Crippa, Keila Maria Ceresér, Miréia Fortes Vianna-Sulzbach, Érico de Moura Silveira Júnior, Gabriel Santana da Rosa, Manoella Guatimuzim Testa da Silva, Gabriel Henrique Hizo, Leonardo Simão Medeiros iD, Carlos Eduardo Santana de Oliveira, Giovana Bristot, Alline Cristina Campos und 6 weitere

The Canadian Journal of Psychiatry · 2024-04 · 69 (4) · 242-251

DOI: 10.1177/07067437231209650 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 03.11.2023. Verfasst von Jairo Vinícius Pinto und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. Hauptthemen laut MEDLINE: Bipolar Disorder, Cannabidiol, Psychotic Disorders. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The treatment of bipolar depression remains challenging due to the limited effective and safe therapeutic options available; thus, developing newer treatments that are effective and well tolerable is an urgent unmet need. The objective of the present trial was to test 150 to 300 mg/day of cannabidiol as an adjunctive treatment for bipolar depression.

Method

A randomized, double-blind, placebo-controlled pilot study to assess the efficacy of adjunctive cannabidiol in bipolar depression was used. Efficacy parameters were changes in the Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to week 8. Secondary outcomes included response and remission rates, changes in anxiety and psychotic symptoms, and changes in functioning. Patients continued double-blind treatment until week 12 to monitor for adverse effects, laboratory analysis, and manic symptoms. Study registry: NCT03310593.

Results

A total of 35 participants were included. MADRS scores significantly decreased from baseline to the endpoint (placebo, −14.56; cannabidiol, −15.38), but there was no significant difference between the groups. Similarly, there were no other significant effects on the secondary outcomes. However, an exploratory analysis showed a significant effect of cannabidiol 300 mg/day in reducing MADRS scores from week 2 to week 8 (placebo, −6.64; cannabidiol, −13.72). There were no significant differences in the development of manic symptoms or any other adverse effects.

Conclusion

Cannabidiol did not show significantly higher adverse effects than placebo. Despite the negative finding on the primary outcome, an exploratory analysis suggested that cannabidiol should be further studied in bipolar depression in higher doses of at least 300 mg/day and under research designs that could better control for high placebo response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderCannabidiolPsychotic DisordersHumansPilot ProjectsDepressionDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

Trouble bipolairebipolar depressionbipolar disordercannabidiolcannabinoidscannabinoïdesclinical trialdépression bipolaireessai clinique.essai randomisé contrôlémood disordersrandomized controlled trial

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • Graduate Programme in Psychiatry and Behavioural Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • University Hospital, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
  • Department of Neuroscience and Behavioural Sciences, University of São Paulo, Ribeirão Preto, SP, Brazil.
  • National Institute for Science and Technology in Translational Medicine (INCT-TM), CNPq/FAPESP/CAPES, Ribeirão Preto, Brazil.
  • Graduate Programme in Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.

ORCID-Profile: Jairo Vinícius Pinto, Leonardo Simão Medeiros, Márcia Kauer-Sant'Anna

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Pinto, J. V., Crippa, J. A. S., Ceresér, K. M., Vianna-Sulzbach, M. F., Silveira Júnior, É. M., Santana da Rosa, G., Testa da Silva, M. G., Hizo, G. H., Simão Medeiros, L., Santana de Oliveira, C. E., Bristot, G., Campos, A. C., Guimarães, F. S., Hallak, J. E. C., Zuardi, A. W., Yatham, L. N., Kapczinski, F., & Kauer-Sant'Anna, M. (2024). Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote. The Canadian Journal of Psychiatry, 69(4), 242-251. https://doi.org/10.1177/07067437231209650

Vancouver

Pinto JV, Crippa JAS, Ceresér KM, Vianna-Sulzbach MF, Silveira Júnior ÉM, Santana da Rosa G, et al. Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote. The Canadian Journal of Psychiatry. 2024;69(4):242-251. doi:10.1177/07067437231209650

BibTeX
@article{Pinto2024,
  author = {Pinto, Jairo Vinícius and Crippa, José Alexandre S and Ceresér, Keila Maria and Vianna-Sulzbach, Miréia Fortes and Silveira Júnior, Érico de Moura and Santana da Rosa, Gabriel and Testa da Silva, Manoella Guatimuzim and Hizo, Gabriel Henrique and Simão Medeiros, Leonardo and Santana de Oliveira, Carlos Eduardo and Bristot, Giovana and Campos, Alline Cristina and Guimarães, Francisco Silveira and Hallak, Jaime E C and Zuardi, Antonio W and Yatham, Lakshmi N and Kapczinski, Flávio and Kauer-Sant'Anna, Márcia},
  title = {Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote},
  journal = {The Canadian Journal of Psychiatry},
  year = {2024},
  volume = {69},
  number = {4},
  pages = {242--251},
  doi = {10.1177/07067437231209650}
}
Kostenlos starten →